Recently, the stock price of Eris Lifesciences Ltd. (Eris) corrected by ~22 from 52-week high of Rs.728 as the company has reported below expected numbers in the recent quarters. Eris focuses on lifestyle related disorders, which are chronic in nature. Hence, the main target of the company is specialist and super specialist doctors. It is mainly into select therapeutic areas, such as, CVS, antidiabetics, vitamins, gastroenterology, anti-infectives and gynecology. In FY17, chronic segment generated 66% of total revenues. Even in the acute segment (34% of total revenues), the company focuses on...